John P. Furey

As Chief Executive Officer, John P. Furey leads the company’s development of its novel patient-specific vaccines and immunotherapy strategies for the treatment of malignant gliomas and other cancers. He also serves on the Imvax Board.

Most recently, John was Chief Operating Officer of Spark Therapeutics, Inc., where he led the successful US launch of LUXTURNA™, the first FDA-approved gene therapy for a genetic disease, and contributed to the build out of Spark as a fully integrated company. Prior to Spark, Mr. Furey served as Senior Vice President and Head of Global Operations at Baxalta, where he transformed the company’s global operations into a first-in-class supply chain network for rare diseases and led the 14,000-employee manufacturing, quality, engineering and process development organization. Earlier in his career, Mr. Furey initiated the restructuring and ultimate divestiture of Baxter International’s vaccines franchise to Pfizer. While at Pfizer, he transformed the China vaccine business into one of the company’s fastest growing units.

Mr. Furey also currently serves as non-executive director at Adaptimmune, a leader in T-cell therapy, and is an indepdent board member of Sensorion, a pioneering clinical-stage biopharmaceutical company developing therapies for the ear.

Mr. Furey earned an Executive MBA (Pharmaceutical Marketing) from St Joseph’s University, in Philadelphia, a Bachelor of Science with Honors from Trinity College, Dublin, and a Diploma in Environmental Health from the Dublin Institute of Technology.